Elaine Chen is a reporter who has written for various publications including STAT, The New York Times, and BioRxiv. Her work covers a range of topics including healthcare, business, and scientific research. Elaine has a keen interest in exploring the intersection of health, technology, and society.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Elaine Chen's coverage primarily focuses on healthcare, pharmaceuticals, and to a lesser extent finance. Her articles frequently cite data and press releases. Sources with access to relevant research findings or industry statistics may find success in pitching to her.
Given the prevalence of topics related to obesity, weight-loss drugs, and health research in her articles, Elaine would likely welcome insights from medical professionals specializing in these areas. Additionally, she might be interested in hearing from experts able to provide context around new developments within the pharmaceutical industry.
As Elaine does not have a specific geographic focus mentioned but covers international news across healthcare and finance sectors, she is likely open to receiving pitches from sources located anywhere globally who can offer valuable insights into these industries.
This information evolves through artificial intelligence and human feedback. Improve this profile .
From my colleague Jason Mast: Sarepta announced yesterday that it's discontinuing its next generation of exon-skipping drugs for Duchenne muscular dystrophy over safety concerns.
By: Adam Feuerstein, Allison DeAngelis, Elaine Chen
By: Elaine Chen
AbbVie’s experimental treatment for schizophrenia failed to significantly help patients in two trials, a blow to the company.
Neurogene shares tumbled 35% last night after it disclosed that a pediatric patient with Rett syndrome experienced a severe side effect following treatment with a high dose of its experimental gene therapy.
By: Elaine Chen
On Tuesday, a tiny shred of data on Amgen's lead obesity candidate — not yet verified — erased $12 billion in market value.
By Elaine Chen Nov. 13, 2024 This story first appeared in The Readout newsletter. Sign up for The Readout and receive STAT's award-winning biotech news delivered straight to your inbox.
By Elaine Chen Nov. 14, 2024 This story first appeared in The Readout newsletter. Sign up for The Readout and receive STAT's award-winning biotech news delivered straight to your inbox.
By: Elaine Chen, Adam Feuerstein, Allison DeAngelis
(833) 317-6278 
